The 0.5-mg dose showed an effect on exploratory end points including a 26 % decrease in celiac disease patient-reported outcome symptomatic days ( P = .017 ) , a 31 % increase in improved symptom days ( P = .034 ) , a 50 % or more reduction from baseline of the weekly average abdominal pain score for 6 or more of 12 weeks of treatment ( P = .022 ) , and a decrease in the nongastrointestinal symptoms of headache and tiredness ( P = .010 ) .